Latest1 information on COVID-19
©2022 Stanford Medicine
Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
Not Recruiting
Trial ID: NCT01326364
Purpose
The purpose of this study is first, to determine whether baseline perfusion characteristics
of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to
treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to
determine whether baseline perfusion characteristics in those patients with resectable
pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel
density and vascular endothelial growth factor (VEGF) expression.
Official Title
Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
Stanford Investigator(s)
Brendan C. Visser, MD
Associate Professor of Surgery (General Surgery)
George A. Poultsides, MD, MS, FACS
Professor of Surgery (General Surgery) at the Stanford University Medical Center
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Dominik Fleischmann
Professor of Radiology (Cardiovascular Imaging)
Eligibility
Inclusion Criteria:
1. suspected and/or biopsy-proven pancreatic adenocarcinoma, and
2. referral to Radiology for pre-treatment baseline pancreatic protocol CT.
Exclusion criteria:
1) are absolute contraindications to intravenous iodinated contrast or CT scan.
Intervention(s):
procedure: Stereotactic body radiotherapy
drug: Iodixanol
drug: Iohexol
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
ccto-office@stanford.edu
650-498-7061